CO6450670A2 - Biomarcador para monitorear pacientes - Google Patents
Biomarcador para monitorear pacientesInfo
- Publication number
- CO6450670A2 CO6450670A2 CO11120337A CO11120337A CO6450670A2 CO 6450670 A2 CO6450670 A2 CO 6450670A2 CO 11120337 A CO11120337 A CO 11120337A CO 11120337 A CO11120337 A CO 11120337A CO 6450670 A2 CO6450670 A2 CO 6450670A2
- Authority
- CO
- Colombia
- Prior art keywords
- biomarcator
- immunotherapy
- monitor patients
- methods
- field
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Abstract
La presente invención es en el campo de la inmunoterapia y se refiere a métodos para determinar la eficacia de ciertos tratamientos de inmunoterapia. Los métodos de la invención incluyen medir un biomarcador especial en algún momento después de la iniciación del tratamiento de inmunoterapia para evaluar el resultado clínico del citado tratamiento. La invención tiene por consiguiente aplicaciones al campo de la medicina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305256 | 2009-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6450670A2 true CO6450670A2 (es) | 2012-05-31 |
Family
ID=42153802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11120337A CO6450670A2 (es) | 2009-03-24 | 2011-09-16 | Biomarcador para monitorear pacientes |
Country Status (21)
Country | Link |
---|---|
US (1) | US20120028279A1 (es) |
EP (1) | EP2411815B1 (es) |
JP (1) | JP5774578B2 (es) |
KR (1) | KR20110138354A (es) |
CN (1) | CN102362184B (es) |
AU (1) | AU2010227611B2 (es) |
BR (1) | BRPI1009892A2 (es) |
CA (1) | CA2756133A1 (es) |
CO (1) | CO6450670A2 (es) |
DK (1) | DK2411815T3 (es) |
ES (1) | ES2555858T3 (es) |
HK (1) | HK1161644A1 (es) |
HU (1) | HUE026194T2 (es) |
IL (1) | IL214611A (es) |
MX (1) | MX2011010061A (es) |
NZ (1) | NZ595290A (es) |
RU (1) | RU2542435C2 (es) |
SG (2) | SG174507A1 (es) |
TW (1) | TWI470225B (es) |
WO (1) | WO2010108908A1 (es) |
ZA (1) | ZA201106890B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2452194T3 (en) | 2009-07-10 | 2015-11-30 | Transgene Sa | Biomarker PATIENT SELECTION AND RELATED PRACTICES |
WO2013177470A1 (en) * | 2012-05-23 | 2013-11-28 | Genentech, Inc. | Selection method for therapeutic agents |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
WO1998035267A1 (en) * | 1997-02-06 | 1998-08-13 | University College Dublin | Electrochromic system |
CA2282300C (en) * | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
JPH10306029A (ja) * | 1997-03-07 | 1998-11-17 | Akira Hayashi | 細菌の菌体成分を有効成分とする癌免疫療法剤 |
CN1248919A (zh) * | 1997-03-07 | 2000-03-29 | 林昭 | 以细菌菌体成分为有效成分的癌症免疫治疗剂 |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9819726D0 (en) | 1998-09-11 | 1998-11-04 | Advanced Environmental Enginee | Vapour recovery system |
US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
EP1147181B1 (en) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
JP4334174B2 (ja) | 1999-11-15 | 2009-09-30 | オニックス ファーマシューティカルズ,インコーポレイティド | 腫瘍崩壊性アデノウイルス |
AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
IL154712A0 (en) | 2000-11-23 | 2003-10-31 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
JP2004533421A (ja) * | 2001-03-27 | 2004-11-04 | バイオミラ,インコーポレイテッド | T1免疫応答とt2免疫応答との間で調節するためのワクチン |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
AT500647A1 (de) * | 2002-05-21 | 2006-02-15 | Igeneon Krebs Immuntherapie | Verwendung eines impfstoffes |
SI1509244T1 (sl) * | 2002-06-06 | 2011-11-30 | Immunicum An | Nov postopek in spojina za izdelavo celične alogenične vakcine |
ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US20040197304A1 (en) * | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
AU2004280630A1 (en) * | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc. | Method |
FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
CA2553377A1 (en) * | 2004-01-13 | 2005-07-28 | Dnavec Research Inc. | Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimaulatory cytokines |
WO2005118884A1 (en) * | 2004-05-28 | 2005-12-15 | The United States Of America As Represented By The Secretary Of The Navy | A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines |
CN101035901A (zh) * | 2004-07-22 | 2007-09-12 | 细胞基因系统有限公司 | 腺病毒载体中转基因的插入 |
EP2269636A3 (en) * | 2004-10-25 | 2011-04-06 | Statens Serum Institut | Chlamydia trachomatis antigens for vaccine and diagnostic use |
CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
CN101309697A (zh) * | 2005-06-28 | 2008-11-19 | 拜奥米拉公司 | 用一种粘蛋白状糖蛋白(muc-1)疫苗治疗患者的方法 |
US20090305258A1 (en) * | 2006-02-17 | 2009-12-10 | Paolo La Colla | Methods for the diagnosis of proliferative and/or conformational diseases |
WO2009034961A1 (ja) * | 2007-09-10 | 2009-03-19 | Riken | ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤 |
-
2010
- 2010-03-23 HU HUE10709742A patent/HUE026194T2/en unknown
- 2010-03-23 CA CA2756133A patent/CA2756133A1/en not_active Abandoned
- 2010-03-23 JP JP2012501278A patent/JP5774578B2/ja not_active Expired - Fee Related
- 2010-03-23 SG SG2011068335A patent/SG174507A1/en unknown
- 2010-03-23 US US13/260,223 patent/US20120028279A1/en not_active Abandoned
- 2010-03-23 EP EP10709742.0A patent/EP2411815B1/en not_active Not-in-force
- 2010-03-23 BR BRPI1009892A patent/BRPI1009892A2/pt not_active IP Right Cessation
- 2010-03-23 AU AU2010227611A patent/AU2010227611B2/en not_active Ceased
- 2010-03-23 DK DK10709742.0T patent/DK2411815T3/en active
- 2010-03-23 MX MX2011010061A patent/MX2011010061A/es active IP Right Grant
- 2010-03-23 WO PCT/EP2010/053755 patent/WO2010108908A1/en active Application Filing
- 2010-03-23 RU RU2011142612/15A patent/RU2542435C2/ru not_active IP Right Cessation
- 2010-03-23 NZ NZ595290A patent/NZ595290A/xx not_active IP Right Cessation
- 2010-03-23 SG SG2014014021A patent/SG2014014021A/en unknown
- 2010-03-23 KR KR1020117022284A patent/KR20110138354A/ko active IP Right Grant
- 2010-03-23 CN CN201080013134.7A patent/CN102362184B/zh not_active Expired - Fee Related
- 2010-03-23 ES ES10709742.0T patent/ES2555858T3/es active Active
- 2010-03-24 TW TW99108736A patent/TWI470225B/zh not_active IP Right Cessation
-
2011
- 2011-08-11 IL IL214611A patent/IL214611A/en not_active IP Right Cessation
- 2011-09-16 CO CO11120337A patent/CO6450670A2/es not_active Application Discontinuation
- 2011-09-21 ZA ZA2011/06890A patent/ZA201106890B/en unknown
-
2012
- 2012-02-29 HK HK12102114.3A patent/HK1161644A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ595290A (en) | 2012-09-28 |
JP2012521549A (ja) | 2012-09-13 |
TWI470225B (zh) | 2015-01-21 |
US20120028279A1 (en) | 2012-02-02 |
CN102362184B (zh) | 2015-04-08 |
SG2014014021A (en) | 2014-07-30 |
ZA201106890B (en) | 2012-06-27 |
AU2010227611A1 (en) | 2011-08-25 |
RU2011142612A (ru) | 2013-04-27 |
CA2756133A1 (en) | 2010-09-30 |
EP2411815B1 (en) | 2015-11-11 |
RU2542435C2 (ru) | 2015-02-20 |
SG174507A1 (en) | 2011-10-28 |
IL214611A (en) | 2015-07-30 |
HUE026194T2 (en) | 2016-05-30 |
ES2555858T3 (es) | 2016-01-11 |
MX2011010061A (es) | 2011-11-18 |
AU2010227611B2 (en) | 2014-05-29 |
HK1161644A1 (en) | 2012-07-27 |
EP2411815A1 (en) | 2012-02-01 |
JP5774578B2 (ja) | 2015-09-09 |
TW201038943A (en) | 2010-11-01 |
IL214611A0 (en) | 2011-09-27 |
CN102362184A (zh) | 2012-02-22 |
DK2411815T3 (en) | 2015-11-30 |
WO2010108908A1 (en) | 2010-09-30 |
KR20110138354A (ko) | 2011-12-27 |
BRPI1009892A2 (pt) | 2016-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12012024A (es) | Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados | |
TR201904638T4 (tr) | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
EA201490230A1 (ru) | Применение меченых ингибиторов hsp90 | |
AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
DOP2011000045A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
ECSP13012913A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
DOP2015000070A (es) | Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide | |
ECSP12012134A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
TR201907241T4 (tr) | IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. | |
CO2017007383A2 (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
CO6592030A2 (es) | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa | |
MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
BR112014011488A2 (pt) | medicamento para tratamento terapêutico e/ou melhora de sépsis | |
CO6440591A2 (es) | Biomarcardor para monitorear pacientes | |
CO6731081A2 (es) | Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol | |
BR112015005583A2 (pt) | método para o diagnóstico de um fenótipo molecular de um paciente que sofre de uma doença associada à inflamação crônica | |
CO6450670A2 (es) | Biomarcador para monitorear pacientes | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
BR112013025197A2 (pt) | métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer | |
EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |